SOX30 and AIDS dementia complex: The percentage of SOX30 high-expression samples was significantly decreased from stageI (36.21%, 42/116), II (35.90, 14/39), III (23.21, 13/56) to IV (6.25%, 1/16) groups in ADC patients (p = 0.023) (Table 1), but was not statistically different among stage I (22.08%, 17/77), II (21.67%, 13/60) and III + IV (12.00%, 6/50) groups in SCC patients (p = 0.315) (Additional file 1: Table S2).